Everolimus News and Research

RSS

Trial findings do not support prasugrel monotherapy at the time of primary PCI for STEMI patients

Monotherapy using prasugrel failed to show noninferiority compared with potent antiplatelet therapy plus aspirin at the time of primary percutaneous coronary intervention for ST-segment elevation myocardial infarction.

29 Aug 2026

Novel PRRT approach shows promise in advanced neuroendocrine tumors

A new type of peptide receptor radionuclide therapy (PRRT) appears to be safe in metastatic neuroendocrine tumor patients who have exhausted conventional treatment options.

31 May 2026

New target identified to overcome resistance in neuroendocrine tumors

Neuroendocrine cells are unique in their ability to act both as nerve cells and hormone-making cells.

6 Apr 2026

Mayo Clinic researchers develop experimental nanotherapy to treat aggressive brain tumors

Mayo Clinic researchers developed an experimental nanotherapy that delivers two cancer drugs directly to brain tumors, according to a study published in Communications Medicine.

6 Apr 2026

UT San Antonio study evaluates rapamycin’s potential to promote healthy aging

UT Health San Antonio, the academic health center of The University of Texas at San Antonio (UT San Antonio) is launching a multi-phase clinical study to better understand how the drug rapamycin may promote healthy aging.

25 Mar 2026

Oral combination regimen improves survival in ER-positive HER-2-negative breast cancer

Patients with estrogen-receptor-positive HER-2-negative advanced breast cancer showed significantly improved progression-free survival when treated with an oral combination regimen that includes giredestrant, a novel, next-generation selective estrogen receptor degrader and full antagonist, compared to a standard combination approach.

18 Oct 2025

Targeted therapy combination shows superior outcomes in advanced kidney cancer

Results from a trial led by researchers from The University of Texas MD Anderson Cancer Center showed that a targeted therapy combination improved outcomes for patients with metastatic clear-cell renal carcinoma (ccRCC) – a type of kidney cancer – whose disease progressed following immunotherapy.

18 Oct 2025

Combination treatment approach shows promise for hard-to-treat triple-negative breast cancer

A new study led by researchers at the Icahn School of Medicine at Mount Sinai has found that adding the targeted therapy everolimus to standard carboplatin chemotherapy extends the time before disease progression in patients with advanced triple-negative breast cancer (TNBC), one of the most aggressive and hard-to-treat forms of breast cancer.

21 Aug 2025

New mechanism uncovered behind immune decline after tuberculosis treatment

Researchers at Baylor College of Medicine and collaborating institutions have discovered a mechanism that drives the long-term decline in immune response that is observed after tuberculosis (TB) has been successfully treated.

1 Oct 2024

Belzutifan shows promise in treating advanced renal cell carcinoma

The LITESPARK-005 phase 3 clinical enrolled 746 patients with metastatic clear cell renal cell carcinoma (ccRCC) who had progressed after treatment with both an immune checkpoint inhibitor (ICI) and an anti-angiogenic therapy.

21 Aug 2024

Research uncovers cells-of-origin for breast cancer in BRCA2 mutation carriers

Australian scientists have pinpointed likely 'cells-of-origin', the source cells that can grow into breast cancer, in women carrying a faulty BRCA2 gene who are at high risk of developing the disease.

16 Jan 2024

Organoid study opens new avenues in pulmonary neuroendocrine cancer therapy

Researchers performed a molecular analysis of neuroendocrine neoplasm (NEN) patient-derived tumor organoids (PDTOs) and their parental neoplasms.

13 Dec 2023

HIF-2α inhibitor belzutifan significantly reduces progression of clear cell renal cell carcinoma

Belzutifan significantly reduced the risk of progression of clear cell renal cell carcinoma (ccRCC), the most common type of kidney cancer, in patients previously treated with immune checkpoint inhibitors and anti-angiogenic therapies compared with everolimus in a phase 3 clinical trial.

24 Oct 2023

Everolimus after surgery may benefit patients with very-high-risk clear cell renal cell carcinoma

A secondary analysis from the SWOG S0931 EVEREST trial has found that in the subgroup of patients with clear-cell renal cell carcinoma (RCC) who were at very-high risk of recurrence, those who were treated with everolimus after surgery had a statistically significant improvement in recurrence-free survival compared to patients getting placebo after surgery.

22 Oct 2023

New animal model replicates the development of cardiac sarcoidosis

Sarcoidosis is an inflammatory disease in which immune cells form tissue nodules in various organs, which can drastically impair organ function.

5 Oct 2023

Dual-antiplatelet therapy should remain the standard strategy for PCI even in the drug-eluting stent era

Prasugrel monotherapy after percutaneous coronary intervention (PCI) with drug-eluting stents is not superior to dual-antiplatelet therapy (DAPT) for major bleeding but is non-inferior for cardiovascular events in patients with acute coronary syndrome (ACS) or high bleeding risk (HBR), according to late breaking research presented in a Hot Line session today at ESC Congress 2023.

28 Aug 2023

Single-cell transcriptomic analysis reveals specific cellular signatures for kidney transplant rejection

Imagine a day when a urine test could inform a doctor precisely why a kidney transplant patient was experiencing organ rejection and suggest the best medication for specifically addressing the problem.

28 Jun 2023

Bioresorbable vascular scaffolds may be just as effective as drug-eluting metal stents for treating heart disease patients

First-generation bioresorbable vascular scaffolds (BVS) may be just as effective as drug-eluting metallic stents, which are currently the standard treatment for heart disease patients undergoing percutaneous coronary intervention (PCI).

17 May 2023

Rapamycin and other rapalogs have potential to delay cancer

A new research perspective was published in Oncotarget's Volume 14 on April 14, 2023, entitled, "Cancer prevention with rapamycin."

18 Apr 2023

Combinatorial biomarker predicts response to immunotherapy in kidney cancer patients

The number of immune cells in and around kidney tumors, the amount of dead cancer tissue, and mutations to a tumor suppressor gene called PBRM1 form a biomarker signature that can predict — before treatment begins — how well patients with kidney cancer will respond to immunotherapy, according to new research directed by investigators at the Johns Hopkins Kimmel Cancer Center and its Bloomberg~Kimmel Institute for Cancer Immunotherapy.

6 Apr 2023